Stay Current with the Latest Key Advances
Through engaging lectures, case studies, and virtual microscopy sessions, Masters of Pathology Series – Lung Pathology helps build and translate knowledge into realistic diagnostic scenarios. Course Director Lynette M. Sholl, MD, and her colleagues deliver in-depth coverage of topics like granulomatous diseases, vasculitis, multiple lung tumors, lung transplant pathology, pulmonary vascular pathology, benign mimics of lung cancer, and more. This CME course will help you to better:
– Recognize common, uncommon mediastinal tumors including thymic neoplasms
– Interpret the clinical implications of specific carcinoma diagnoses
– Identify effective diagnostic and predictive biomarkers for NSCLC diagnosis
– Differentiate between reactive and neoplastic proliferations of the lung and pleura
– Understand the relevance of IHC, FISH, molecular tests for diagnosing malignant mesothelioma
– Define appropriate biomarkers to select lung cancer patients for immunotherapy
CHECK SAMPLES
1. Pleura
|
1
|
Mesothelioma – Marina Vivero, MD |
|
2
|
Lymphohistiocytic Neoplasms of the Lung and Pleura and their Differential – A Pulmonary Pathologist’s Perspective – Lynette M. Sholl, MD |
2. Mediastinum
|
1
|
Thymic Pathology: Hyperplasia, Thymoma, and Neuroendocrine Tumors – Lynette M. Sholl, MD |
|
2
|
Thymic Carcinoma and other Anterior Mediastinal Malignancies – Lynette M. Sholl, MD |
3. Neuroendocrine Tumors
|
1
|
Typical and Atypical Carcinoid and Precursor Lesions – Marina Vivero, MD |
|
2
|
High Grade Neuroendocrine Carcinomas of the Lung – Lynette M. Sholl, MD |
4. Non-Small Cell Lung Carcinomas
|
1
|
Clinical and Pathologic Features of Pulmonary Squamous Cell Carcinoma – Lynette M. Sholl, MD |
|
2
|
Clinical and Pathologic Features of Adenocarcinoma of the Lung – Lynette M. Sholl, MD |
|
3
|
Lepidic-Predominant Tumors: Rules for Classification and Implications for Staging – Lynette M. Sholl, MD |
|
4
|
Poorly Differentiated and Undifferentiated Tumors of the Lung – Lynette M. Sholl, MD |
|
5
|
Benign Mimics of Lung Cancer – Lynette M. Sholl, MD |
5. Immunohistochemistry for Lung Cancer
|
1
|
Immunohistochemistry for Lung Carcinomas: Diagnosis – Lynette M. Sholl, MD |
|
2
|
Immunohistochemistry for Lung Cancer: Prediction – Lynette M. Sholl, MD |
6. Biomarkers in Lung Cancer
|
1
|
Genomic Biomarkers for Non Small Cell Lung Carcinoma – Lynette M. Sholl, MD |
|
2
|
Overview of Immunotherapy Biomarkers for NSCLC – Lynette M. Sholl, MD |
7. Interstitial Lung Diseases
|
1
|
Interstitial Lung Disease Pathology – Robert F. Padera, Jr., MD, PhD |
|
2
|
Granulomatous Diseases – Lynette M. Sholl, MD |
|
3
|
Microscopy Session: Infectious Diseases – Robert F. Padera, Jr., MD, PhD |
|
4
|
Connective Tissue Disease – Interstitial Lung Disease – Marina Vivero, MD |
|
5
|
Lung Transplant Pathology – Robert F. Padera, Jr., MD, PhD |
|
6
|
Smoking – Related Lung Diseases – Lynette M. Sholl, MD |
|
7
|
Pulmonary Vascular Pathology – Robert F. Padera, Jr., MD, PhD |
|
8
|
Vasculitis – Lynette M. Sholl, MD |
8. Survival Sessions
|
1
|
Managing Small Biopsies for Lung Cancer – Specimen Handling for Optimal Diagnostic and Predictive Testing – Lynette M. Sholl, MD |
|
2
|
Microscopy Session: Interpretation of PD-L1 Immunohistochemistry – Lynette M. Sholl, MD |
|
3
|
Atypical Epithelial Proliferation in the Lung: Is It Reactive or Neoplastic? – Lynette M. Sholl, MD |
|
4
|
Multiple Lung Tumors: Same or Different? – Lynette M. Sholl, MD |
|
5
|
Potpourri of Pulmonary Problems: Special T, N, M Challenges in Lung Cancer Pathology – Lynette M. Sholl, MD |
|
6
|
Microscopy Session: Cytology of Lung Cancers – Marina Vivero, MD |
|
7
|
Reactive Pleuritis vs. Mesothelioma – Making the Distinction – Lynette M. Sholl, MD |
Learning Objectives
At the conclusion of this course, the participant will be able to do the following:
– Identify the pathologic and immunohistochemical features of common lung carcinomas and understand the clinical implications of specific carcinoma diagnoses.
– Identify the crucial diagnostic and predictive biomarkers for non-small cell lung carcinomas and understand how to apply them in clinical practice.
– Define appropriate biomarkers for selection of lung cancer patients for immunotherapy.
– Distinguish between reactive and neoplastic proliferations of the lung and pleura.
– Recognize common and uncommon mediastinal tumors including thymic neoplasms.
– Recognize clinically significant interstitial changes in the lung in patients with and without prospectively recognized clinical and radiographic correlates.examinations
Intended Audience
This educational activity was designed for practicing pathologists, oncologists, pulmonologists, and pathology assistants.
Designation
Date of Original Release: June 1, 2019
Date Credits Expire: June 1, 2022
Estimated Time to Complete: 15.75 hours
